INTERIM REPORT 1 JANUARY - 30 SEPTEMBER 2021 

 

Q3 2021

  • The result for the quarter amounted to -5 043 kSEK (-5 346 kSEK)
  • Cash flow for the quarter amounted to -6 414 kSEK (-165 kSEK)
  • Cash and cash equivalents at the end of the quarter amounted to 19 564 kSEK (39 561 kSEK)

 

Download Excel

Summary Financial Highlights
kSEK
July-sep
2021
July-sep
2020
Jan-sep
2021
Jan-sep
2020
Jan-dec
2020
Net revenue 0 0 0 0 0
Operating result -5,045 -5,317 -14,643 -14,006 -17,235
Result -5,043 -5,346 -14,686 -14,035 -17,289
Balance sheet total 29,348 42,720 29,348 42,720 39,640
Cash flow -6,141 -165 -14,056 37,497 31,556
Cash and cash equivalents 19,564 39,561 19,564 39,561 33,620
Equity ratio % 82% 93% 82% 93% 92%
           
Data per share
SEK
         
Number of shares at the end of the period 9,806,200 9,606,200 9,806,200 9,606,200 9,606,200
Result per share before and after dilution* -0.51 -0.56 -1.51 -1.75 -2.06
Cash flow per share -0.63 -0.02 -1.45 4.68 3.75
Equity per share 2.46 4.13 2.46 4.13 3.79
           
* Dilution effects is not calculated when the result is negative          

Significant events during Q3 (July-Sep)

On the 1st of September Anna Lönn started as Development director

 

Significant events during Q1-Q2 (Jan-June)

Ziccum published its goals for 2021 on January 12. The major goals are to enter into the first licensing agreement for one or more dry-formulated vaccines, and to present a detailed plan for establishing a modular Fill and Finish production facility for filling and final packaging of dry, thermostable powder vaccines, including the necessary partnerships and financing plans. Ziccum’s medium-term goal (2–3 years) is to establish the first Fill and Finish facility for dry-formulated vaccines in Sweden.

On January 25 Ziccum announced the extension of the evaluation agreement with Janssen Vaccine & Prevention B.V. (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) that was entered into on October 3, 2019. The purpose is to finalize the analysis of Ziccum’s air-drying capabilities on one of Janssen’s vaccine platform technologies.

On March 17 Ziccum announced that the company has been accepted as a member of NIIMBL, the US National Institute for Innovation in Manufacturing Biopharmaceuticals. NIIMBL drives innovation and uptake of new technologies within biopharmaceutical manufacturing in the US. NIIMBL is among others funded by the US National Institute of Standards and Technology (NIST) and the U.S. Department of Commerce and is able to distribute federal grants.

At the General Meeting it was decided to adopt two long-term incentive programs: one for the Board of Directors, consisting of warrants (LTI 2021/2024), and another one for the employees consisting of employee stock options (LTI 2021:1).

The warrant program LTI 2018/2021 has also closed, and all warrants were exercised. The warrant program was assigned to the Board of Directors and consisted of 200 000 warrants, with a vesting period during 26 April – 26 May 2021. To finance the share subscription, the warrant holders have sold 120 000 warrants to a long-term investor, who has also exercised the warrants. The exercise price was 11 SEK per share, hence 2.2 mSEK was added to Ziccum through the share subscriptions. The exercised warrants increased the number of shares and votes with 200 000 and the total amount of shares is hereby 9 806 200.

Significant events after the reporting period

Nothing significant to report

 

 

Latest updated: 10/26/2021 8:00:32 AM by Frida Hjelmberg